Current Scheduling Status
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
ECDD Technical summary
Fencamfamin, chemically N-ethyl-3-phenylbicyclo[2,2,1]heptan-2-amine, is a central nervous system stimulant with a pharmacological profile that resembles that of amphetamine in most aspects. The toxicology of fencamfamin also resembles that of amphetamine, but it does not produce aggregate toxicity. Fencamfamin is not metabolized to amphetamine and has a half-life of about 16 hours. Experimentally, fencamfamin is self-administered by both beagle dogs and monkeys and it shows the typical pattern of a central stimulant reinforcer. There is no evidence of clinical abuse liability or serious public health or social problems associated with its use or abuse, but there have been:a few reports of social abuse by students
im some countries. Fencamfamin has been used clinically as an "‘energizing’"’ drug since 1962 and is marketed in 32 countries, being prescriptioncontrolled in many of them. There are a few examples of illicit trafficking in fencamfamin. On the basis of the data outlined above, it was the consensus of the Expert Committee that fencamfamin met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances and should be placed in Schedule IV of the Convention.
Fencamfamin, chemically N-ethyl-3-phenylbicyclo[2,2,1]heptan-2-amine, is a central nervous system stimulant with a pharmacological profile that resembles that of amphetamine in most aspects. The toxicology of fencamfamin also resembles that of amphetamine, but it does not produce aggregate toxicity. Fencamfamin is not metabolized to amphetamine and has a half-life of about 16 hours. Experimentally, fencamfamin is self-administered by both beagle dogs and monkeys and it shows the typical pattern of a central stimulant reinforcer. There is no evidence of clinical abuse liability or serious public health or social problems associated with its use or abuse, but there have been:a few reports of social abuse by students
im some countries. Fencamfamin has been used clinically as an "‘energizing’"’ drug since 1962 and is marketed in 32 countries, being prescriptioncontrolled in many of them. There are a few examples of illicit trafficking in fencamfamin. On the basis of the data outlined above, it was the consensus of the Expert Committee that fencamfamin met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances and should be placed in Schedule IV of the Convention.
ECDD Recommendation
Inclusion in Schedule IV of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_729.pdf1.29 MB